Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/102023
Type: Artigo de periódico
Title: Efficacy And Safety Of Cox-2 Selective Inhibitor Versus Non Selective Nsaid In The Symptomatic Treatment Of Primary Dysmenorrhea [eficácia E Segurança Do Uso Do Inibidor Seletivo Da Cox-2 Versus Antiinflamatório Não Esteróide Clásico No Tratamento Sintomático Da Dismenorréia Primária]
Author: Martinez Alcala F.O.
Aldrete Velasco J.A.
Risco Cortes R.J.
De Mello N.R.
Chada Baracat E.
Tomaz G.
Camargos A.
Bedone A.J.
Barbosa I.C.
De Souza R.N.
Ortega Rumi D.
Abstract: Objective: Assessment of efficacy and safety of a COX-2 selective inhibitor compared with a classic NSAID over a treatment period of 3-5 days, during 3 menstrual cycles, for primary dysmenorrhea. Study design: Multicentre, multi-national, double-blind, double-dummy, parallel 3 groups, randomised trial, Phase IIIb, 337 patients. Treatment group comparisons of continuous variables were carried out using the Kruskal-Wallis-test and Wilcoxon signed rank tests. Efficacy was analysed using Fisher and Chi-square tests. Results: Cox-2 selective inhibitor showed a similar profile in the pain reduction and dysmenorrhea symptoms when compared with mefenamic acid. Fourty-nine subjects presented adverse events. Almost the half of those 49 subjects were in the mefenamic acid group. There were no differences between the safety profiles of the two meloxicam dosages. Conclusion: Cox-2 selective NSAID were comparable with classic NSAID in relieving dysmenorrhea symptoms and it seems to have a better gastro-intestinal tolerability profile.
Editor: 
Rights: fechado
Identifier DOI: 
Address: http://www.scopus.com/inward/record.url?eid=2-s2.0-0344982785&partnerID=40&md5=acdf1d4855f0b64ae51fe6fd8331567d
Date Issue: 2003
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-0344982785.pdf4.82 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.